Welcome to our dedicated page for Turn Therapeutics news (Ticker: TTRX), a resource for investors and traders seeking the latest updates and insights on Turn Therapeutics stock.
Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company whose news flow centers on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. Company updates frequently highlight progress in its lead program GX-03, a topical IL-36/IL-31 pathway inhibitor in a phase 2 trial for moderate to severe atopic dermatitis, as well as other late-stage clinical programs in eczema and onychomycosis.
News releases from Turn Therapeutics regularly cover clinical milestones, such as enrollment updates, safety summaries, and timing for interim and topline data from its phase 2 eczema study. Investors and observers can also follow announcements related to its thermostable intranasal vaccine initiative, including stability data for a live, lipid-enveloped vaccine formulated with the PermaFusion platform and the planned in-vivo and in-vitro studies for an intranasal influenza vaccine candidate.
Corporate and strategic developments are another key theme in TTRX news. The company has reported its direct listing on Nasdaq, capital strategy using flexible financing arrangements, and a global supply, development, and license agreement with Medline to develop and commercialize PermaFusion-based products in professional and retail markets. Governance updates, including the appointments of experienced board members and a Vice President of Corporate Communications, also feature prominently.
Turn Therapeutics additionally issues communications on shareholder engagement efforts, such as webinar series and public discussions involving its leadership on topics like healthcare communication and public trust in science. For readers tracking TTRX, this news page offers a centralized view of clinical progress, partnership activity, financing developments, and corporate governance changes over time.
Turn Therapeutics (Nasdaq: TTRX) launched a shareholder communications initiative including a recurring webinar series and a Founder Blog by CEO Bradley Burnam.
The first live webinar is scheduled for October 22, 2025 at 2:00 PM ET via webcast; recordings and materials will be posted to the investor relations website immediately after each session. The Founder Blog will share ongoing company updates, research insights, and perspectives, with additional blog details to be announced later this week.
Turn notes three FDA clearances for its wound and dermatology formulations and ongoing late-stage clinical programs in eczema and onychomycosis.
Turn Therapeutics (NASDAQ:TTRX) announced on October 15, 2025 that Kent E. Kester, MD, FACP, FIDSA, FASTMH, has been appointed to its Board of Directors.
Dr. Kester is described as a retired U.S. Army Colonel and an infectious disease physician with senior leadership experience in clinical development, translational medicine, vaccine and anti-infective innovation, and public-private global health collaborations, including service as Commander of the Walter Reed Army Institute of Research. The company said his experience will support late-stage programs, regulatory milestones, governance, and strategic direction as Turn advances its dermatology, wound, and anti-infective therapies.
Turn Therapeutics (NASDAQ:TTRX) appointed Arthur Golden to its Board of Directors effective Oct 14, 2025. Mr. Golden brings corporate governance and legal expertise, including 24 years as a director at Emerson Electric and more than 40 years as a partner and now Senior Counsel at Davis Polk & Wardwell. The company said his experience in M&A, shareholder relations, compliance, and cross-border governance will support oversight as Turn advances its late-stage dermatology, wound, and anti-infective programs.
The CEO framed the hire as strengthening governance, strategic execution, and capital-market navigation during a critical growth inflection for the company.
Turn Therapeutics (NASDAQ:TTRX) announced its common stock will commence trading today, October 8, 2025, on the Nasdaq Capital Market under the ticker TTRX.
The company's Form S-1 was declared effective by the SEC on September 30, 2025. Founder and CEO Bradley Burnam will participate in a Closing Bell ceremony at 4:00 PM ET on October 8, 2025, broadcast live from Nasdaq MarketSite. Financial advisor and legal counsel were named: Clear Street LLC (financial advisor) and Davis Polk and Wardwell (legal counsel).